1. Introduction {#sec1-ijerph-17-05454}
===============

Alzheimer's disease and related dementia (ADRD) is a group of serious neurodegenerative disorders characterized by progressive decline in cognitive and psychomotor function \[[@B1-ijerph-17-05454],[@B2-ijerph-17-05454]\]. Prevalence of ADRD continues to increase worldwide, exacting enormous social, economic and healthcare costs. For example, in the United States, at least 5.8 million adults are living with Alzheimer's disease (AD), the most common form of dementia, with attributable Medicare costs alone exceeding \$146 billion annually; these figures are expected to rise steeply in coming years \[[@B3-ijerph-17-05454]\]. ADRD is also a significant contributor to mortality and number of life years lived with disability \[[@B3-ijerph-17-05454],[@B4-ijerph-17-05454]\]. With no cure for ADRD, and no effective disease-modifying treatments yet available despite decades of clinical research \[[@B5-ijerph-17-05454]\], efforts are increasingly shifting to prevention and early intervention, including intensive approaches to identify and target modifiable risk factors for ADRD \[[@B6-ijerph-17-05454]\].

To date, several factors have been linked to elevated ADRD risk. These include non-modifiable factors such as advancing age, female sex, rurality, and specific genetic profiles, as well as modifiable risk factors \[[@B7-ijerph-17-05454]\]. The latter include: poor education and poverty \[[@B7-ijerph-17-05454],[@B8-ijerph-17-05454]\]; physical inactivity, midlife obesity, and other lifestyle factors \[[@B7-ijerph-17-05454],[@B9-ijerph-17-05454]\]; history of head injury or stroke \[[@B10-ijerph-17-05454],[@B11-ijerph-17-05454]\]; and certain chronic physical health disorders (e.g., diabetes, cardiovascular disease, midlife hypertension, respiratory illness \[[@B7-ijerph-17-05454],[@B9-ijerph-17-05454],[@B12-ijerph-17-05454]\]). Specific mental health conditions (e.g., depression, anxiety) and chronic sleep impairment have also been shown to predict subsequent cognitive decline and conversion to ADRD \[[@B13-ijerph-17-05454],[@B14-ijerph-17-05454],[@B15-ijerph-17-05454],[@B16-ijerph-17-05454]\]. In addition, there is growing evidence from observational and experimental research that chronic pain, an increasingly common and highly burdensome condition, may also contribute to elevated risk for neurocognitive impairment and development of ADRD \[[@B17-ijerph-17-05454],[@B18-ijerph-17-05454],[@B19-ijerph-17-05454],[@B20-ijerph-17-05454],[@B21-ijerph-17-05454],[@B22-ijerph-17-05454],[@B23-ijerph-17-05454]\].

Although limited at present, there is evidence from longitudinal studies that chronic pain and common non-cancer chronic pain conditions (NCPC) may increase risk for incident cognitive impairment and ADRD \[[@B24-ijerph-17-05454],[@B25-ijerph-17-05454],[@B26-ijerph-17-05454],[@B27-ijerph-17-05454],[@B28-ijerph-17-05454],[@B29-ijerph-17-05454],[@B30-ijerph-17-05454],[@B31-ijerph-17-05454],[@B32-ijerph-17-05454],[@B33-ijerph-17-05454],[@B34-ijerph-17-05454]\]. For example, recent retrospective cohort investigations of Taiwanese nationals \[[@B26-ijerph-17-05454],[@B28-ijerph-17-05454],[@B29-ijerph-17-05454],[@B34-ijerph-17-05454]\] and prospective cohort studies of Japanese and Norwegian elders \[[@B25-ijerph-17-05454],[@B27-ijerph-17-05454],[@B33-ijerph-17-05454]\] have reported significantly increased risk of incident dementia in adults previously diagnosed with fibromyalgia \[[@B28-ijerph-17-05454]\], osteoarthritis or knee pain \[[@B26-ijerph-17-05454],[@B33-ijerph-17-05454]\], and headache \[[@B25-ijerph-17-05454],[@B27-ijerph-17-05454],[@B29-ijerph-17-05454],[@B34-ijerph-17-05454]\]. Likewise, findings from a handful of longitudinal studies in US \[[@B24-ijerph-17-05454],[@B30-ijerph-17-05454],[@B32-ijerph-17-05454]\] and British adults \[[@B31-ijerph-17-05454]\] suggest that non-specific chronic pain may predict subsequent deterioration in memory \[[@B30-ijerph-17-05454],[@B32-ijerph-17-05454]\], accelerated cognitive decline \[[@B32-ijerph-17-05454]\], new onset cognitive impairment \[[@B32-ijerph-17-05454]\], and incident dementia \[[@B24-ijerph-17-05454],[@B32-ijerph-17-05454]\], although studies varied widely in design, study population, length of follow-up, and measures. However, to our knowledge, no study has investigated the collective and incremental association of common chronic pain conditions to ADRD risk, nor the potential mediating role of depression, anxiety and sleep disorders, conditions strongly and bidirectionally associated with chronic pain and linked to ADRD risk.

In this study, we investigate the association of common NCPC to ADRD risk using multiple retrospective cohorts from a linked database of nationally representative sample of older US Medicare beneficiaries. We hypothesized that the presence of NCPC at baseline will be associated with significantly increased risk of incident ADRD, and that the magnitude of this association will increase with rising number of NCPC at baseline. We further hypothesized that depression, anxiety and/or sleep impairment, will partially mediate the association between NCPC and incident ADRD.

2. Methods {#sec2-ijerph-17-05454}
==========

2.1. Study Design {#sec2dot1-ijerph-17-05454}
-----------------

Our study used a retrospective cohort design to assess the association of baseline common non-cancer chronic pain conditions (NCPC) to incident ADRD using data from the Medicare Current Beneficiary Survey (MCBS) \[[@B35-ijerph-17-05454]\] linked with Medicare fee-for-service claims. MCBS is a nationally representative survey of adults participating in Medicare health insurance program. As detailed below, multiple three-year MCBS cohorts (2001--2013) were pooled to construct the analytic sample for this study.

2.2. Data Source {#sec2dot2-ijerph-17-05454}
----------------

First initiated in 1991, MCBS has been recruiting survey participants each year using a complex stratified, three-stage probability sampling design described in detail elsewhere \[[@B36-ijerph-17-05454],[@B37-ijerph-17-05454]\]. MCBS participants undertake structured in-person interviews at baseline and follow-up rounds each year for up to three years. MCBS generates comprehensive cross-sectional and longitudinal data on participants' health status, health services utilization, prescription medications, and payment sources using a combination of survey and administrative records. Our study used data from MCBS Cost and Use files linked with Medicare fee-for-service claims to ascertain demographics, access to care, lifestyle factors, medical history and medication. Based on the recommendations by MCBS investigators \[[@B36-ijerph-17-05454],[@B37-ijerph-17-05454],[@B38-ijerph-17-05454]\] and sampling strategies documented in prior published studies using MCBS \[[@B36-ijerph-17-05454],[@B38-ijerph-17-05454],[@B39-ijerph-17-05454]\], we combined 11 MCBS cohorts in order to maximize reliability and precision of our study estimates; these included the following cohorts: 2001--2003; 2002--2004; 2003--2005; 2004--2006; 2005--2007; 2006--2008; 2007--2009; 2008--2010; 2009--2011; 2010--2012 and 2011--2013.

2.3. Study Sample {#sec2dot3-ijerph-17-05454}
-----------------

The study sample comprised continuously fee-for-service enrolled community-dwelling Medicare beneficiaries, aged 65 years or over, who had complete information on NCPC status and were still alive at the end of follow-up. Institutionalized participants were excluded, as were participants with diagnosed ADRD at baseline. As depicted in the sample selection flow chart (see [supplementary Figure S1](#app1-ijerph-17-05454){ref-type="app"}), application of all a priori exclusion criteria yielded a final sample size of 16,934 adults (N's by year = 1874 (2001--2003); 1768 (2002--2004); 1884 (2003--2005); 1766 (2004--2006); 1735 (2005--2007); 1650 (2006--2008); 1495 (2007--2009); 1278 (2008--2010); 1034 (2009--2011); 1159 (2010--2012); and 1291 (2011--2013)).

IRB/ethics approval: The present study was approved as exempt protocol by the WVU Institutional Review Board (IRB), due to the deidentified nature of the data used in the study.

2.4. Dependent Variable: Incident Alzheimer's Disease and Related Dementia (ADRD) at Follow-Up-- Yes/No {#sec2dot4-ijerph-17-05454}
-------------------------------------------------------------------------------------------------------

The Medicare fee-for-service (FFS) claims for inpatient (IP), skilled nursing facility (SNF), outpatient (OT), home health agency (HHA), and physician office (PO) visits for years 2001--2013 as well as MCBS self-reported Health Status and Functioning files were used to ascertain the presence of ADRD at baseline and follow-up. The presence of ADRD at both baseline (year 1) and follow-up (years 2 and 3) was ascertained using a validated CMS algorithm (Centers for Medicare and Medicaid Services (CMS) Chronic Condition Algorithms) \[[@B40-ijerph-17-05454]\] of at least one fee-for-service claim with any of these International Classification of Diseases, ninth Edition, clinical modification (ICD-9-CM) diagnostic codes: 331.0, 331.11, 331.19, 331.2, 331.7, 290.0, 290.10, 290.11, 290.12, 290.13, 290.20, 290.21, 290.3, 290.40, 290.41, 290.42, 290.43, 294.0, 294.10, 294.11, 294.20, 294.21, 294.8, and 797, or an affirmative response to the self-reported Health Status question "Has a doctor ever told you that you had Alzheimer's?" \[[@B41-ijerph-17-05454]\]. Using a combination of claims and survey data to ascertain ADRD has been recommended by MCBS investigators to increase capture of ADRD and has been shown to yield results similar to those of expert in-person-assessment \[[@B42-ijerph-17-05454]\].

2.5. Key Independent Variable: Non-Cancer Chronic Pain Condition (NCPC) and Number of NCPCs {#sec2dot5-ijerph-17-05454}
-------------------------------------------------------------------------------------------

Baseline NCPC were identified using Medicare fee-for-service claims. NCPC included five common NCPC (back or neck pain, headache, joint pain, neuropathic pain, and osteoarthritis). The presence of any NCPC was identified using either two outpatient claims (90 days apart) or one inpatient claim using ICD9-CM codes as recommended by the Centers for Medicare and Medicaid Services \[[@B40-ijerph-17-05454]\] and consistent with prior studies of NCPC \[[@B43-ijerph-17-05454],[@B44-ijerph-17-05454]\]. Any NCPC was assessed as a binary variable (yes/no) during baseline. Relative NCPC burden was ascertained with a count variable (0--5 NCPCs).

2.6. Covariates {#sec2dot6-ijerph-17-05454}
---------------

To account for the influence of potential confounding, specific baseline characteristics known or suspected to be associated with ADRD risk and/or chronic pain based on prior research were selected a priori for inclusion as covariates in our multivariable models. These included age group (65--69, 70--74, 75--79, and ≥80 years), based on prior research indicating the risk in adults doubles approximately every 4 years after age 65 \[[@B3-ijerph-17-05454],[@B45-ijerph-17-05454]\]. Other biological factors i.e., sex (female/male), and race/ethnicity (Non-Hispanic White, African American, Hispanic, and other); other demographic characteristics, i.e., marital status (married, widowed, divorce/separated, other), educational level (less than high school, high school, some college, college), family income, measured as percentage of federal poverty line (FPL) (poor/low-income (\<200%), (middle to high-income (≥200%)); health insurance status (insured by Medicaid (yes/no) or private insurance (yes/no)); rurality (metropolitan areas, yes/no); and lifestyle factors, i.e., smoking status (current smoker, past smoker, never smoked) and body mass index (BMI, kg/m^2^) (underweight (\<18.5), normal (18.5--24.9), overweight (25--29.9), and obese ≥30).

Also included as covariates were other chronic physical health conditions reported at baseline (yes/no). These included hypertension, diabetes, heart disease, respiratory illness, and history of stroke, traumatic brain injury (TBI), and cancer (with the exception of non-melanotic skin cancer), as well as specific auto-immune conditions associated with chronic pain, including rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). In addition, certain commonly used medications that have been linked to ADRD risk and/or used in chronic pain management were also evaluated as covariates. These included non-steroidal anti-inflammatory drugs (NSAIDS) \[[@B46-ijerph-17-05454]\], opioid analgesics \[[@B47-ijerph-17-05454]\], benzodiazepines \[[@B48-ijerph-17-05454]\] and certain other psychotropic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), monoamino oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), and atypical antidepressants) \[[@B49-ijerph-17-05454]\]. Benzodiazepine use was evaluated as a separate medication category given that: (1) a significant number of study participants (10%) were prescribed these medications; and (2) prior research has suggested that benzodiazepines not only has multidimensional neurological effects \[[@B50-ijerph-17-05454],[@B51-ijerph-17-05454]\], but is also associated with elevated risk for ADRD \[[@B48-ijerph-17-05454]\].

*Mediators:* To examine the potential mediating influence of mood and sleep disorders on the relation of NCPC to incident ADRD, we evaluated the effects of diagnosed depression, anxiety and insomnia-related sleep disorders both separately and in combination (see [supplementary Table S1](#app1-ijerph-17-05454){ref-type="app"} for ICD-9-CM diagnostic codes).

2.7. Statistical Analysis {#sec2dot7-ijerph-17-05454}
-------------------------

Potential differences in baseline characteristics by NCPC and ADRD status were determined using Rao-Scott chi-square tests (categorical variables). Logistic regressions were used to assess the unadjusted and independent association of NCPC and NCPC burden to incident ADRD. In these multivariable logistic regressions, we carried out block-wise adjustment for demographic and socioeconomic factors; lifestyle factors and chronic physical health conditions; and analgesics and psychotropic medications to assess the adjusted associations of NCPC to ADRD risk. Similar nested multivariable logistic regression models were used to evaluate potential mediating effects of baseline diagnoses of depression, anxiety, and sleep disorders both individually and in combination. To assess the linear relationship of NCPC to risk of ADRD, regression models with polynomial contrast were used. For our sensitivity analyses, we used multinomial logistic regression to build competing risk of death models with the following four outcomes: ADRD-free and alive at the end of follow-up (N = 15,785) (referent category); ADRD-free and not alive at the end of follow-up (N = 1220); ADRD positive and Alive at the end of follow-up (N = 1149); ADRD positive and not alive at the end of follow-up (N = 259).

All bivariate and multivariable analyses were carried out using MCBS complex survey design sampling weights. MCBS data-cycles are released with cross-sectional as well as longitudinal weights. We used 3-year backward longitudinal weights for analysis of our pooled cohorts to yield up to two years of continuous follow-up. All analyses were performed using SAS survey procedure (SAS version 9.4, SAS Institute, Inc.).

3. Results {#sec3-ijerph-17-05454}
==========

Our analytical sample comprised 16,934 eligible participants with a mean age at baseline of 74 ± 0.07 years. The majority of the cohort were female (57%), white (83%), married (56.5%) and reported a family income at or above 200% of the FPL. Study participants were predominantly from metropolitan areas (71%) and most had private insurance (79%).

Overall baseline prevalence of any NCPC in this study was 36% (weighted), with significant differences by cohort (range 31% to 39%, *p* \< 0.0001). Pain burden in this population was high, with 37.5% reporting at least two co-existing NCPCs and 15% indicating three or more NCPCs. A significantly higher percentage of participants with baseline NCPC reported a history of chronic physical health conditions associated with ADRD, including hypertension (82% vs. 68.7%), heart disease (31.5% vs. 19.9%), stroke (14% vs. 10%), diabetes (23.5% vs. 19%) (*p*'s \< 0.0001). Participants with baseline NCPC were also significantly more likely to report mood disorders, including depression (11% vs. 4.5%) and anxiety (7.9% vs. 3.5%), as well as sleep disorders (25.5% vs. 10.2%) when compared to participants without baseline NCPC ([Table 1](#ijerph-17-05454-t001){ref-type="table"}).

[Table 2](#ijerph-17-05454-t002){ref-type="table"} summarizes the baseline characteristics of the study sample by incident ADRD status. A total of 1149 participants were diagnosed with incident ADRD during the 2-year follow-up period (overall incidence rate = 6.8 per 100 participants). Incident ADRD rates did not differ by study cohorts (range 4.9 to 6.2 per 100, *p* = 0.9), and were significantly higher in women (6.2% vs. 5.0% in men), and in participants who were black (7.4% vs. 5.5% in Non-Hispanic whites), widowed (8.2% vs. 4.5% in married), and more poorly educated (*p*'s \< 0.0001). The proportion of participants diagnosed with incident ADRD was also significantly higher in those who were \<200% of the federal poverty level (7.4% vs. 4.3%), were on Medicaid (9.1% vs. 5.2%) and who lacked private insurance (7.2% vs. 5.3%) (*p*'s \< 0.0001). In addition, the percentage diagnosed with ADRD was significantly greater in those who indicated a history of specific physical health conditions at baseline, including hypertension, heart disease, stroke, and TBI, as well as in those who reported use of opioid analgesics (6.9% vs. 5.4%), benzodiazepines (8.5% vs. 5.4%), or other psychotropics (9.8% vs. 4.8%) (*p*'s \< 0.0001). The proportion of participants with incident ADRD increased significantly with rising number of comorbid physical health conditions (range 4.6% to 10.6%, *p* \< 0.0001). Participants who reported sleep, depression or anxiety disorders at baseline also included a significantly higher proportion of ADRD cases (*p*'s \< 0.0001). Notably, as detailed in [Table 2](#ijerph-17-05454-t002){ref-type="table"}, incident ADRD rates were significantly higher in those who reported any NCPC at baseline (6.6 vs. 4.3 per 100), and rose with increasing number of NCPC conditions, from 6.2 in those with 1 NCPC condition to 17.3 per 100 participants in those with 4 or more NCPC conditions (*p*'s \< 0.0001).

3.1. Association of NCPC to Incident ADRD {#sec3dot1-ijerph-17-05454}
-----------------------------------------

In our unadjusted logistic regression model, those with baseline NCPC were 54% more likely to have incident ADRD (odds ratio (OR) = 1.54, 95% confidence interval (CI) = 1.34--1.78, *p* \< 0.0001) ([Table 3](#ijerph-17-05454-t003){ref-type="table"}). Adjustment for demographic and socioeconomic characteristics (sex, race, age, education, poverty, Medicaid insurance, private insurance, and marital status) attenuated but did not eliminate this association (adjusted OR (AOR) = 1.33, 95% confidence interval (CI) =1.14--1.53, *p* \< 0.0001).

The magnitude of this association was modestly reduced after additional adjustment for lifestyle factors and comorbid physical health conditions (AOR = 1.28, CI 1.10--1.48, *p* = 0.001), and further attenuated by inclusion of medications in the model (AOR adjusted for NSAIDs and opioid analgesics (AOR = 1.25, CI 1.08--1.45, *p* = 0.003) ([Table 3](#ijerph-17-05454-t003){ref-type="table"}). Further adjustment for benzodiazepines and other psychotropics only slightly reduced the magnitude of this estimate (AOR = 1.21 (1.04--1.40, *p* = 0.01)). As detailed in [Table 3](#ijerph-17-05454-t003){ref-type="table"}, the association of NCPC to incident ADRD rose significantly in both strength and magnitude with increasing number of pain conditions. Relative to beneficiaries with no NCPC at baseline, those with ≥4 NCPCs were twice as likely to be subsequently diagnosed with ADRD after adjustment for demographics, socioeconomic status, lifestyle factors, and medical conditions (AOR = 1.98, CI = 1.36--2.89, *p*-trend \<0.00001). Further adjustment for analgesic medications only slightly attenuated these associations (AOR for ≥4 vs. no NCPC = 1.91, CI 1.31--2.80, *p*-trend = 0.0008). When number of NCPCs at baseline were assessed as a continuous variable, risk for incident ADRD increased 12% for each additional NCPC in the fully adjusted model (AOR = 1.12, CI = 1.06--1.20, *p* = 0.0007).

3.2. Sensitivity Analyses {#sec3dot2-ijerph-17-05454}
-------------------------

Analyses using competing risk of death models yielded findings consistent with those from our primary analyses ([Table 4](#ijerph-17-05454-t004){ref-type="table"}). Relative to participants without NCPC at baseline, those with any NCPC and still alive at follow-up were significantly more likely to be diagnosed with incident ADRD after adjustment for demographics, lifestyle characteristics, physical health conditions, analgesics, and other factors (AOR for any NCPC = 1.26, 95% CI = 1.08--1.46, *p* \< 0.003). In contrast, baseline NCPC status was unrelated to death during the follow-up period, either with or without a diagnosis of incident ADRD (AORs, respectively = 0.99 and 0.97, *p*'s ≥ 0.6). Further adjustment for psychotropics did not appreciably change these estimates. These findings suggest survival bias is unlikely to explain the positive association observed between baseline NCPC and incident ADRD.

3.3. Potential Mediating Effects of Sleep and Mood Disorders {#sec3dot3-ijerph-17-05454}
------------------------------------------------------------

As illustrated in [Table 5](#ijerph-17-05454-t005){ref-type="table"}, inclusion of mood disorders in fully adjusted model modestly attenuated the relation of NCPC to incident ADRD (AORs for any NCPC and 4+ NCPCs vs. no NCPC, respectively = 1.17 (1.01--1.37) and 1.57 (1.06--2.34), *p*'s ≤ 0.04). Likewise, the addition of sleep disorders to the model attenuated the association of NCPC to ADRD risk (AORs for any NCPC and 4+ NCPCs vs. no NCPC, respectively = 1.20 (1.04--1.39) and 1.66 (1.12--2.45) *p*'s \< 0.02) as did that of both sleep and mood disorders (AORs for any NCPC and 4+ NCPCs, respectively = 1.18 (1.01--1.38) and 1.41 (0.94--2.12)). Adding mood and sleep disorders to models adjusted only for sociodemographics yielded similar risk estimates (AORs for any NCPC = 1.19, CI 1.02--1.47, *p* \< 0.05), again suggesting that mood and sleep disorders may in part mediate the relation of NCPC to incident ADRD. Additional adjustment for benzodiazepines and psychotropics did not appreciably alter these associations (AOR = 1.17, CI = 1.01--1.37, *p* = 0.04). A number of demographic, lifestyle, and health-related factors remained significantly associated with incident ADRD in our fully adjusted models. These include: black (vs. non-Hispanic white) race (AOR = 1.48, CI 1.09--2.00); age (80+ vs. 65--69, AOR 6.12, CI = 4.7--7.9); poverty (\<200% vs. \>200%, AOR 1.17, CI = 1.02--1.34); Medicaid insurance (AOR 1.27, 95% CI = 1.01--1.6); BMI (underweight vs. normal, AOR = 1.48, CI = 1.04--2.12); history of stroke (AOR 1.87, CI = 1.6--2.2) or TBI (AOR = 1.52, CI = 1.04--2.23); and psychotropic medications (AOR = 2.04, CI = 1.74--2.39) (*p*'s \< 0.05). Use of neither NSAIDs nor opioids was significantly associated with ADRD risk in the adjusted analyses (AORs respectively = 0.96 (0.80--1.16) and 1.03 (0.87--1.22)), nor was use of benzodiazepines (AOR = 1.17, CI = 0.97--1.40) (*p*'s \> 0.05).

4. Discussion {#sec4-ijerph-17-05454}
=============

In this retrospective cohort study of older community-dwelling Medicare fee-for-service enrollees, diagnosed NCPC at baseline remained significantly and positively associated with risk for incident ADRD after adjustment for demographics, socioeconomic factors, medical history, medications, and other factors. The strength and magnitude of this association rose with increasing number of NCPCs, indicating increasing risk for incident ADRD with rising chronic pain condition burden. The relation between NCPC and risk of ADRD appeared to be mediated in part by the presence of sleep and mood disorders. To our knowledge, this investigation is the first large retrospective cohort study to assess the collective and incremental association of NCPC to incident ADRD, and to explore the potential mediating role of mood and sleep disorders in this association.

The significant positive associations NCPC to ADRD risk observed in this study are consistent with those of prior longitudinal studies regarding the relation of specific chronic pain conditions to risk for dementia. Recent large retrospective matched cohort studies in Taiwanese nationals \[[@B26-ijerph-17-05454],[@B28-ijerph-17-05454],[@B29-ijerph-17-05454],[@B34-ijerph-17-05454],[@B52-ijerph-17-05454]\], prospective cohort investigations in Norwegian adults \[[@B25-ijerph-17-05454],[@B27-ijerph-17-05454]\] and a small retrospective cohort study of Canadian elders \[[@B53-ijerph-17-05454]\] all indicated significantly increased risk for incident all-cause dementia in those diagnosed with headache \[[@B25-ijerph-17-05454],[@B27-ijerph-17-05454],[@B29-ijerph-17-05454],[@B34-ijerph-17-05454],[@B52-ijerph-17-05454],[@B53-ijerph-17-05454]\], OA/knee pain \[[@B26-ijerph-17-05454],[@B33-ijerph-17-05454]\], and fibromyalgia \[[@B28-ijerph-17-05454]\] after adjusting for demographics, comorbid conditions, and other potential confounders. Although the few longitudinal studies investigating the association of non-specific chronic pain to subsequent cognitive deterioration or incident ADRD, all in British \[[@B31-ijerph-17-05454]\] and U.S. adults \[[@B24-ijerph-17-05454],[@B30-ijerph-17-05454],[@B32-ijerph-17-05454]\], have varied widely in study population, design, and methodology, results have likewise indicated that severe chronic pain \[[@B30-ijerph-17-05454],[@B31-ijerph-17-05454]\], persistent pain \[[@B32-ijerph-17-05454]\], and/or reported pain interference \[[@B24-ijerph-17-05454]\] may predict subsequent worsening in memory \[[@B30-ijerph-17-05454],[@B31-ijerph-17-05454]\], accelerated cognitive decline \[[@B32-ijerph-17-05454]\], and dementia \[[@B24-ijerph-17-05454],[@B32-ijerph-17-05454]\].

While some longitudinal studies investigating the association between pain and dementia risk have included depression and/or anxiety as covariates in their adjusted models \[[@B24-ijerph-17-05454],[@B28-ijerph-17-05454],[@B29-ijerph-17-05454],[@B30-ijerph-17-05454],[@B32-ijerph-17-05454],[@B34-ijerph-17-05454]\], no studies to our knowledge have explored the potential mediating role of mood disorders or evaluated the influence of sleep impairment on the association of chronic pain to incident ADRD. Sleep and mood disorders are common in older adults, have been strongly and reciprocally associated with chronic pain \[[@B54-ijerph-17-05454],[@B55-ijerph-17-05454]\], and have been shown to be independent risk factors for ADRD \[[@B13-ijerph-17-05454],[@B14-ijerph-17-05454],[@B15-ijerph-17-05454],[@B56-ijerph-17-05454],[@B57-ijerph-17-05454]\], suggesting that sleep and mood impairment may mediate the observed associations between pain and ADRD risk. The role of sleep and mood neuromodulators, such as serotonin \[[@B58-ijerph-17-05454],[@B59-ijerph-17-05454]\], dopamine and histamine \[[@B60-ijerph-17-05454],[@B61-ijerph-17-05454]\] has been well documented in pain expression, likely contributing to the documented bidirectional relationships of sleep \[[@B54-ijerph-17-05454]\] and mood disorders \[[@B55-ijerph-17-05454],[@B62-ijerph-17-05454]\] to pain conditions. In the current study, inclusion of depression, anxiety, and insomnia-related sleep disorders in the model weakened but did not eliminate the observed associations between NCPC and incident ADRD risk, suggesting a partial mediating role. In agreement with prior research, sleep \[[@B15-ijerph-17-05454],[@B54-ijerph-17-05454]\] and mood disorders \[[@B13-ijerph-17-05454],[@B14-ijerph-17-05454],[@B57-ijerph-17-05454]\] remained strongly and positively associated with both baseline NCPC and with risk for incident ADRD in this cohort after adjustment for other factors.

*NCPC and increased ADRD risk; possible pathways:* although the mechanisms underlying the observed association of NCPC to incident ADRD remain speculative, chronic pain may operate via several pathways to increase risk for dementia \[[@B21-ijerph-17-05454],[@B23-ijerph-17-05454],[@B63-ijerph-17-05454],[@B64-ijerph-17-05454],[@B65-ijerph-17-05454]\]. Adults experiencing chronic pain have demonstrated diminished attention, impaired learning and memory, altered processing speed, reduced psychomotor efficiency, and compromised executive function \[[@B17-ijerph-17-05454],[@B18-ijerph-17-05454],[@B19-ijerph-17-05454],[@B22-ijerph-17-05454],[@B23-ijerph-17-05454]\], hallmarks of cognitive decline that may ultimately presage the development of cognitive impairment and dementia. Contributing to the documented decline in cognitive function that accompanies chronic pain, NCPC may promote specific adverse neurostructural and neurofunctional changes. For example, experimental and neuroimaging studies have demonstrated neurodegenerative changes in subjects with chronic pain that parallel those observed in ADRD \[[@B21-ijerph-17-05454],[@B65-ijerph-17-05454],[@B66-ijerph-17-05454]\], including reduction in grey matter volume in the amygdala, hippocampus and frontal cortices, the brain regions integrally involved in cognitive and behavioral functioning \[[@B66-ijerph-17-05454],[@B67-ijerph-17-05454]\]. The increases in both peripheral and systemic inflammation that have been linked to chronic pain \[[@B68-ijerph-17-05454],[@B69-ijerph-17-05454]\] may contribute to these neurodegenerative changes by contributing to neuroinflammation \[[@B63-ijerph-17-05454]\]. For example, chronic pain-induced microglial neuroinflammation has been directly implicated in Alzheimer's disease pathogenesis via production of amyloid beta plaques and neurofibrillary tangles \[[@B21-ijerph-17-05454]\]; persistent inflammation negatively affects neuroplasticity and synaptic performance via reduction in brain-derived neurotrophic factors \[[@B66-ijerph-17-05454],[@B68-ijerph-17-05454],[@B69-ijerph-17-05454]\]. Neuronal receptors in the brain are neither infinite nor mutually exclusive and serve a range of neurologic functions under limited resources. During persistent pain, nerve endings fire rapid pain impulses to the brain for remedial actions, which in turn, exhausts the neuronal resources that are also involved in cognitive functions \[[@B69-ijerph-17-05454],[@B70-ijerph-17-05454],[@B71-ijerph-17-05454]\]. In addition, the presence of chronic pain conditions has been correlated with dysregulation of noradrenergic-modulated endogenous pain autoinhibition \[[@B69-ijerph-17-05454]\], which has, in turn, been linked to negative cognitive outcomes, including decline in working and long-term memory \[[@B70-ijerph-17-05454],[@B71-ijerph-17-05454]\].

In agreement with previously published research \[[@B3-ijerph-17-05454],[@B7-ijerph-17-05454],[@B45-ijerph-17-05454]\], risk for ADRD increased strongly with age in this study, and was elevated among African Americans and in adults who had less education or lower family income, were on Medicaid, or had a history of diabetes, stroke, or TBI. Similarly, the significant positive relationships between baseline sleep and mood disorders and likelihood of incident ADRD observed in this sample of US Medicare beneficiaries are consistent with the findings of numerous prior investigations \[[@B14-ijerph-17-05454],[@B15-ijerph-17-05454]\]. Both psychotropics and analgesics are frequently employed to manage chronic mood disorders, insomnia, and pain conditions in the older population. NSAIDs have been reported to reduce risk of ADRD in most but not all studies \[[@B46-ijerph-17-05454]\], whereas prior research has demonstrated modest or no association of opioid analgesics to ADRD risk \[[@B47-ijerph-17-05454]\]. In this study, use of neither NSAIDs nor opioid analgesics was significantly related to risk for ADRD. In agreement with some \[[@B49-ijerph-17-05454]\] but not all previous studies \[[@B48-ijerph-17-05454],[@B72-ijerph-17-05454]\], use of psychotropics, but not benzodiazepines, remained significantly associated with incident ADRD after adjustment for multiple confounders. However, as noted above, adjustment for these medications only slightly attenuated the observed relationships of NCPCs to incident ADRD.

Strengths and Limitations
-------------------------

This study has several strengths, including the population-based design, the use of longitudinal data from multiple cohorts, and the large, nationally representative sample of U.S. community-dwelling elders enrolled in FFS Medicare plans. Comprehensive information was available on a broad range of demographic and lifestyle characteristics, as well as on medical history, medication use, and other factors, allowing us to assess the potential confounding influence of these factors. Furthermore, NCPC's, medication use, and history of other health conditions were ascertained using claims data and established algorithms. ADRD was identified using a combination of Medicare claims and survey data, likely leading to greater capture of this often under-reported and underdiagnosed outcome \[[@B41-ijerph-17-05454],[@B73-ijerph-17-05454],[@B74-ijerph-17-05454]\]. Notably, previous studies have indicated high specificity (89-95%) and acceptable sensitivity (64-85%) for the ascertainment of ADRD using multiple years of Medicare claims data \[[@B41-ijerph-17-05454],[@B73-ijerph-17-05454],[@B74-ijerph-17-05454]\]. We used a 3-year backward cohort design, with a two-year continuous follow-up and incident ADRD measured at two time points.

Our study also has a number of limitations, including the relatively short follow-up period and lack of information on NCPC duration or on chronic pain symptoms, precluding a more comprehensive assessment of the potential role of chronic pain and chronic pain conditions in the development of ADRD. Given that ADRD is often underdiagnosed and progression is generally slow and insidious, and that the study follow-up period was short, under-ascertainment of ADRD is likely in this study, potentially biasing our risk estimates toward the null. In addition, given that we used a conservative method \[[@B75-ijerph-17-05454]\] for ascertaining chronic pain (i.e., ≥1 inpatient visit or two outpatient visits for any chronic pain conditions 90 days apart), and that NCPC is typically under-reported in medical claims data \[[@B76-ijerph-17-05454],[@B77-ijerph-17-05454],[@B78-ijerph-17-05454]\], NCPC may have been under-ascertained in this study, again potentially biasing risk estimates towards the null. Moreover, as sleep and mood disorders often accompany the development of ADRD, these disorders may have reflected prodromal ADRD in some who were diagnosed with incident ADRD. While we were able to adjust for a wide range of potential confounders, including smoking and BMI, we lacked information on certain lifestyle-related and other factors strongly linked to ADRD risk, including alcohol consumption, physical activity, genetic and familial predisposition, and social isolation \[[@B7-ijerph-17-05454],[@B9-ijerph-17-05454]\]. Due to small cell sizes, we were also unable to adjust for Parkinson's disease and related movement disorders, conditions which have been linked to chronic pain, as well as to mood and sleep disorders and cognitive impairment \[[@B79-ijerph-17-05454],[@B80-ijerph-17-05454]\]. However, small cell sizes would also suggest that any residual confounding from these movement disorders is unlikely to explain our findings. Both ADRD and chronic pain have been associated with increased mortality \[[@B81-ijerph-17-05454],[@B82-ijerph-17-05454],[@B83-ijerph-17-05454]\], introducing potential survival bias. However, competing risk of death analyses yielded findings similar to those of our primary analyses, arguing against a substantive effect of survival bias on our study results. Finally, definitive conclusions regarding causality are not possible due to the short follow-up period in this study and the insidious nature of ADRD development and progression. However, while reverse causality cannot be ruled out, a growing literature suggests chronic pain can disrupt neurocognitive function and may increase risk for cognitive decline and incident dementia \[[@B18-ijerph-17-05454],[@B65-ijerph-17-05454],[@B84-ijerph-17-05454]\], whereas evidence for an inverse relationship remains sparse \[[@B22-ijerph-17-05454]\].

5. Conclusions {#sec5-ijerph-17-05454}
==============

In this large, population-based study in a nationally representative sample of US community-dwelling elders enrolled in FFS Medicare, NCPC at baseline remained significantly and positively associated with risk for incident ADRD after adjustment for demographics, lifestyle factors, medical history, medications, and other factors. This association increased in magnitude with increasing NCPC burden and appeared to be partially mediated by the presence of mood and sleep disorders. Additional large, prospective studies with longer term follow-up are warranted to confirm our findings; to further elucidate the potentially important contribution of chronic pain to accelerated cognitive decline, new onset cognitive impairment and the development of ADRD; to clarify the potential mediating role of sleep and mood disorders; and to explore possible underlying mechanisms.
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###### 

Baseline characteristics by non-cancer chronic pain conditions in older Medicare beneficiaries \*, analyzed using linked data from the Medicare Current Beneficiary Survey and Medicare claims, 2001--2013.

  Variables                          Total    Any NCPC   *p*-Value ^§^                            
  ---------------------------------- -------- ---------- --------------- ------- -------- ------- ----------
  ***ALL*^¥^**                       16,934   100        6369            100.0   10,565   100.0   
  ***Sociodemographics***                                                                         
   **Sex**                                                                                        \<0.0001
   Female                            9669     56.9       4215            66.4    5454     51.5    
   Male                              7265     43.1       2154            33.6    5111     48.5    
  **Age in Years**                                                                                \<0.0001
   65--69                            4188     31.8       1335            26.4    2853     34.9    
   70--74                            3484     22.5       1230            22.1    2254     22.8    
   75--79                            3674     21.4       1411            22.8    2263     20.6    
   80+                               5588     24.3       2393            28.8    3195     21.7    
   **Race/Ethnicity**                                                                             0.842
   White                             14,085   83.2       5293            83.4    8792     83.0    
   Black                             1159     6.7        438             6.7     721      6.7     
   Hispanic                          956      5.6        359             5.7     597      5.6     
   Other                             709      4.5        268             4.3     441      4.6     
   **Education**                                                                                  \<0.0001
   \<High School                     4605     25.0       1744            25.4    2861     24.7    
   High School                       6174     36.4       2349            37.0    3825     36.1    
   Some College                      2431     15.0       950             15.7    1481     14.6    
   College                           3675     23.6       1306            21.9    2369     24.6    
   **Marital Status**                                                                             \<0.0001
   Married                           9139     56.5       3208            52.8    5931     58.7    
   Widowed                           5803     30.6       2491            35.7    3312     27.6    
   Divorce/separated                 1455     9.5        490             8.3     965      10.2    
   Other                             532      3.3        179             3.1     353      3.5     
   **Household Income**                                                                           \<0.0001
   \<200% Federal Poverty Level      8260     45.9       3221            48.4    5039     44.6    
   ≥200% Federal Poverty Level       8674     54.1       3148            51.6    5526     55.4    
  ***Insurance***                                                                                 
   **Medicaid**                                                                                   \<0.0001
   Yes                               2147     11.9       1005            15.4    1142     9.9     
   No                                14,787   88.1       5364            84.6    9423     90.1    
   **Private Insurance**                                                                          0.001
   Yes                               13,418   79.4       5147            80.8    8271     78.5    
   No                                3514     20.6       1221            19.2    2293     21.5    
  ***Residence***                                                                                 
   **Metropolitan Status**                                                                        \<0.0001
   Metro                             11,375   70.6       4415            72.5    6960     69.5    
   Rural                             5558     29.4       1954            27.5    3604     30.5    
  ***Lifestyle Characteristics***                                                                 
   **Body Mass Index**                                                                            \<0.0001
   Underweight                       312      1.7        100             1.4     212      1.8     
   Normal                            5867     34.0       1984            30.4    3883     36.0    
   Overweight                        6709     40.0       2491            39.2    4218     40.5    
   Obese                             3881     24.3       1734            29.0    2147     21.7    
  *Mean BMI 27.2 (±0.052)*                                                                        
   **Smoking Status**                                                                             \<0.0001
   Current                           1594     10.2       457             7.8     1137     11.5    
   Past                              7976     47.5       2965            47.2    5011     47.6    
   Never                             7326     42.4       2936            45.1    4390     40.8    
  ***Baseline Health History***                                                                   
  ***Physical Health Conditions***                                                                
   **Hypertension**                                                                               \<0.0001
   Yes                               12,713   73.5       5263            82.0    7450     68.7    
   No                                4221     26.5       1106            18.0    3115     31.3    
   **Heart disease**                                                                              \<0.0001
   Yes                               4357     24.1       2097            31.5    2260     19.9    
   No                                12,577   75.9       4272            68.5    8305     80.1    
   **Stroke**                                                                                     \<0.0001
   Yes                               2139     11.5       979             14.3    1160     9.9     
   No                                14,795   88.5       5390            85.7    9405     90.1    
   **Diabetes**                                                                                   \<0.0001
   Yes                               3495     20.7       1468            23.5    2027     19.2    
   No                                13,439   79.3       4901            76.5    8538     80.8    
   **Respiratory disease**                                                                        \<0.0001
   Yes                               2423     14.2       1045            16.7    1378     12.7    
   No                                14,511   85.8       5324            83.3    9187     87.3    
   **Cancer**                                                                                     \<0.0001
   Yes                               7101     40.3       2911            44.4    4190     38.0    
   No                                9833     59.7       3458            55.6    6375     62.0    
   **Traumatic Brain Injury**                                                                     \<0.0001
   Yes                               221      1.2        146             2.2     75       0.7     
   No                                16,713   98.8       6223            97.8    10,490   99.3    
   **Rheumatoid Arthritis**                                                                       \<0.0001
   Yes                               508      2.9        349             5.5     159      1.4     
   No                                16,426   97.1       6020            94.5    10,406   98.6    
   **Lupus**                                                                                      \<0.0001
   Yes                               136      0.8        94              1.4     42       0.4     
   No                                16,798   99.2       6275            98.6    10,523   99.6    
  **Number of NCPCs**                                                                             
   0                                 6385     39.1       \-              \-      \-       \-      \-
   1                                 4194     24.4       \-              \-      \-       \-      \-
   2                                 3818     22.0       \-              \-      \-       \-      \-
   3                                 1908     10.9       \-              \-      \-       \-      \-
   ≥4                                629      3.7        \-              \-      \-       \-      \-
  ***Sleep and Mood Disorders***                                                                  
   **Sleep Disorder**                                                                             \<0.0001
   Yes                               2728     15.8       1630            25.5    1098     10.2    
   No                                14,206   84.2       4739            74.5    9467     89.8    
   **Depression**                                                                                 \<0.0001
   Yes                               1158     6.9        686             11.1    472      4.5     
   No                                15,776   93.1       5683            88.9    10,093   95.5    
   **Anxiety**                                                                                    \<0.0001
   Yes                               862      5.1        492             7.9     370      3.5     
   No                                16,072   94.9       5877            92.1    10,195   96.5    
  ***Medication Use***                                                                            
   **NSAIDs**                                                                                     \<0.0001
   Yes                               3241     18.6       1936            30.2    1305     12.0    
   No                                13,693   81.4       4433            69.8    9260     88.0    
   **Opioid Analgesics**                                                                          \<0.0001
   Yes                               3353     19.4       2059            32.2    1294     12.0    
   No                                13,581   80.6       4310            67.8    9271     88.0    
   **Benzodiazepines**                                                                            \<0.0001
   Yes                               1734     9.7        935             14.5    799      7.1     
   No                                15,200   90.3       5434            85.5    9766     92.9    
   **Psychotropic medications**                                                                   \<0.0001
   Yes                               2871     17.0       1448            23.3    1423     13.5    
   No                                14,063   83.0       4921            76.7    9142     86.5    

\* Based on 11 pooled cohorts of 16,934 older community-dwelling adults (age \> 65 years), enrolled in fee-for service Medicare, alive at the end of follow-up. ^¥^ Numbers for some variables may not add up to N = 16,934, due to missing values. ^§^ Statistically significant group differences in presence of NCPC were examined with Rao-Scott chi-square test. Abbreviation: NCPC, non-cancer chronic pain conditions; BMI, body mass index; NSAIDs, nonsteroidal anti-inflammatory drugs.
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###### 

Baseline characteristics by incident Alzheimer's disease and related dementias (ADRD) in older Medicare beneficiaries \*, analyzed using linked data from the Medicare Current Beneficiary Survey and Medicare claims, 2001-2013.

  Variables                          Incident ADRD   *p*-Value ^§^                   
  ---------------------------------- --------------- --------------- -------- ------ ----------
  ***ALL*^¥^**                       1149            6.8             15,785   93.2   
   **Any NCPC**                                                                      \<0.0001
   Yes                               798             6.6             9677     93.4   
   No                                351             4.3             6108     95.7   
   **Number of NCPC's**                                                              \<0.0001
   0                                 351             4.3             6108     95.7   
   1                                 304             6.2             3948     93.8   
   2                                 273             6.0             3605     94.0   
   3                                 155             7.3             1742     92.7   
   ≥4                                66              17.3            382      82.7   
  ***Sociodemographic***                                                             
   **Sex**                                                                           \<0.0001
   Female                            725             6.2             8944     93.8   
   Male                              424             5               6841     95     
   **Age in Years**                                                                  \<0.0001
   65--69                            101             1.9             4087     98.1   
   70--74                            139             4               3345     96     
   75--79                            220             5.9             3454     94.1   
   80+                               689             12              4899     88     
   **Race/Ethnicity**                                                                0.066
   White                             922             5.5             13,163   94.5   
   Black                             106             7.4             1053     92.6   
   Hispanic                          70              5.9             886      94.1   
   Other                             51              6.5             658      93.5   
   **Education**                                                                     \<0.0001
   \<High School                     417             7.8             4188     92.2   
   High School                       398             5.5             5776     94.5   
   Some College                      141             4.8             2290     95.2   
   College                           186             4.1             3489     95.9   
   **Marital Status**                                                                \<0.0001
   Married                           494             4.5             8645     95.5   
   Widowed                           541             8.2             5262     91.8   
   Divorce/separated                 76              4.4             1379     95.6   
   Other                             38              6               494      94     
   **Household Income**                                                              \<0.0001
   \<200% Federal Poverty Level      699             7.4             7561     92.6   
   ≥200% Federal Poverty Level       450             4.3             8224     95.7   
  ***Insurance***                                                                    
   **Medicaid**                                                                      \<0.0001
   Yes                               223             9.1             1924     90.9   
   No                                926             5.2             13,861   94.8   
   **Private Insurance**                                                             \<0.0001
   Yes                               847             5.3             12,571   94.7   
   No                                300             7.2             3214     92.8   
  ***Residence***                                                                    0.649
   **Metropolitan Status**                                                           
   Metro                             787             5.7             10,588   94.3   
   Rural                             362             5.5             5196     94.5   
  ***Lifestyle Characteristics***                                                    
   **Body Mass Index**                                                               \<0.0001
   Underweight                       43              12.2            269      87.8   
   Normal                            484             6.9             5383     93.1   
   Overweight                        417             5.2             6292     94.8   
   Obese                             195             4.3             3686     95.7   
   **Smoking Status**                                                                \<0.0001
   Current                           96              4.8             1498     95.2   
   Past                              472             5               7504     95     
   Never                             580             6.6             6746     93.4   
  ***Baseline Health History***                                                      
  ***Physical Health Conditions***                                                   
   **Hypertension**                                                                  \<0.0001
   Yes                               935             6.3             11,778   93.7   
   No                                214             4.1             4007     95.9   
   **Heart disease**                                                                 \<0.0001
   Yes                               368             7.6             3989     92.4   
   No                                781             5.1             11,796   94.9   
   **Stroke**                                                                        \<0.0001
   Yes                               281             11.9            1858     88.1   
   No                                868             4.9             13,927   95.1   
   **Diabetes**                                                                      0.032
   Yes                               264             6.4             3231     93.6   
   No                                885             5.5             12,554   94.5   
   **Respiratory disease**                                                           0.576
   Yes                               170             5.9             2253     94.1   
   No                                979             5.6             13,532   94.4   
   **Cancer**                                                                        0.043
   Yes                               505             6.2             6596     93.8   
   No                                644             5.3             9189     94.7   
   **Traumatic Brain Injury**                                                        \<0.0001
   Yes                               30              12.8            191      87.2   
   No                                1119            5.6             15,594   94.4   
   **Rheumatoid Arthritis**                                                          0.247
   Yes                               39              6.8             469      93.2   
   No                                1110            5.6             15,316   94.4   
   **Lupus**                                                                         0.119
   Yes                               13              8.9             123      91.1   
   No                                1136            5.7             15,662   94.3   
  ***Sleep and Mood Disorders***                                                     
   **Sleep Disorder**                                                                \<0.0001
   Yes                               267             8.5             2461     91.5   
   No                                882             5.2             13,324   94.8   
   **Depression**                                                                    \<0.0001
   Yes                               170             12.9            988      87.1   
   No                                979             5.1             14,797   94.9   
   **Anxiety**                                                                       \<0.0001
   Yes                               109             10.9            753      89.1   
   No                                1040            5.4             15,032   94.6   
  ***Medication Use***                                                               
   **NSAIDs**                                                                        0.496
   Yes                               226             6               3015     94     
   No                                923             5.6             12,770   94.4   
   **Opioid Analgesics**                                                             \<0.0001
   Yes                               266             6.9             3087     93.1   
   No                                883             5.4             12,698   94.6   
   **Benzodiazepines**                                                               \<0.0001
   Yes                               167             8.5             1567     91.5   
   No                                982             5.4             14,218   94.6   

*\** Based on 11 pooled cohorts of 16,934 older community-dwelling adults (age ≥ 65 years), enrolled in fee-for service Medicare, alive at the end of follow-up. ^¥^ Numbers for some variables may not add up to N = 1149, due to missing values. ^§^ Statistically significant group differences in presence of NCPC were examined with Rao-Scott chi-square test. Abbreviations: NCPC, non-cancer chronic pain conditions; ADRD, Alzheimer's disease and related dementias; NSAIDs, nonsteroidal anti-inflammatory drugs.
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###### 

Association of baseline non-cancer chronic pain conditions (NCPC) and burden to incident Alzheimer's disease and related dementias (ADRD) in older Medicare beneficiaries \*: analysis using linked Medicare Current Beneficiary Survey and Medicare claims data, 2001--2013 (odds ratios (OR) and adjusted odds ratios (AOR) with 95% confidence intervals (CI) calculated using separate logistic regression models).

  NCPC Presence/Number             Unadjusted Model   Model 1 ^¥^   Model 2 ^¥¥^       Model 3 ^ⱡⱡ^                                                    
  -------------------------------- ------------------ ------------- ------------------ -------------- ------------------ ---------- ------------------ ----------
  **Any NCPC \*\* vs. None**       1.54 (1.34,1.78)   \<0.0001      1.33 (1.14,1.53)   \<0.0001       1.28 (1.10,1.48)   0.001      1.25 (1.08,1.45)   0.003
  **Number of NCPCs**                                                                                                                                  
    None (referent)                1.00                             1.00                              1.00                          1.00               
    One                            1.47 (1.26,1.71)   \<0.0001      1.27 (1.08,1.50)   0.0039         1.24 (1.05,1.46)   0.0125     1.23 (1.04,1.45)   0.0179
    Two                            1.42 (1.20,1.68)   \<0.0001      1.25 (1.05,1.49)   0.0121         1.22 (1.02,1.45)   0.0278     1.20 (1.01,1.43)   0.0435
    Three                          1.75 (1.42,2.16)   \<0.0001      1.45 (1.17,1.80)   0.0007         1.38 (1.11,1.71)   0.0041     1.34 (1.07,1.68)   0.0122
    Four or more                   3.03 (2.14,4.29)   \<0.0001      2.32 (1.62,3.31)   \<0.0001       1.98 (1.36,2.89)   0.0004     1.91 (1.31,2.80)   0.0008
  *** P for linear trend ^++^***                      \<0.0001                         \<0.0001                          \<0.0001                      \<0.0001
  **Number of NCPCs**                                                                                                                                  
  (per additional NCPC)            1.23 (1.16,1.30)   \<0.0001      1.16 (1.09,1.23)   \<0.0001       1.13 (1.06,1.20)   0.0002     1.12 (1.05,1.20)   0.0007

\* Based on 11 pooled cohorts of 16,934 older community-dwelling adults (age \> 65 years), enrolled in fee-for-service Medicare. \*\* Including back and neck pain, headache and migraine, joint pain, neuropathic pain and osteoarthritis. ^¥^ Socio-demographics: sex, age, race/ethnicity, education, income, Medicaid insurance, private insurance, marital status, region. ^¥¥^ Lifestyle and chronic physical health conditions: smoking, body mass index, hypertension, diabetes, heart disease, cancer, respiratory disorder, history of stroke, traumatic brain injury. ^ⱡⱡ^ Analgesics: nonsteroidal anti-inflammatory drugs and opioid analgesics. ^++^ Regression results from polynomial contrast for linear relation indicate a strong linear effect of NCPC on risk of ADRD.
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###### 

Association of baseline non-cancer chronic pain conditions to incident Alzheimer's disease and related dementias in older Medicare beneficiaries \*: competing risk analysis using linked Medicare Current Beneficiary Survey (MCBS) and Medicare claims data, 2001--2013 (odds ratios (OR) and adjusted odds ratios (AOR) with 95% confidence intervals (CI) calculated from multinomial logistic regression).

  Any Non-Cancer Chronic Pain Condition (NCPC) \*\*                                       Alive at Follow-Up, No ADRD (Referent)   Alive at Follow-Up, Incident ADRD   Died before Follow-Up, Incident ADRD   Died before Follow-Up, No ADRD                                                  
  --------------------------------------------------------------------------------------- ---------------------------------------- ----------------------------------- -------------------------------------- -------------------------------- ------------------ -------- ------------------ ----------
   **Model 1**. Unadjusted model                                                          1.00                                     \-                                  1.55 (1.34,1.78)                       \<0.0001                         1.29 (1.03,1.62)   0.029    1.25 (1.12,1.40)   \<0.0001
   **Model 2**. Adjusted for sociodemographics ^¥^                                        1.00                                     \-                                  1.34 (1.16,1.55)                       \<0.0001                         1.10 (0.87,1.40)   0.42     1.21 (1.07,1.36)   0.0024
   **Model 3**. Also adjusted for lifestyle and chronic physical health conditions ^¥¥^   1.00                                     \-                                  1.28 (1.11,1.49)                       0.0009                           1.03 (0.79,1.34)   0.8287   1.05 (0.93,1.18)   0.4461
   **Model 4**. Also adjusted for NSAID and opioid analgesic use                          1.00                                     \-                                  1.26 (1.08,1.46)                       0.0026                           0.99 (0.75,1.31)   0.96     0.97 (0.85,1.10)   0.60

\* Based on 11 pooled cohorts of older community-dwelling adults (age \> 65 years), enrolled in fee-for-service Medicare. \*\* Referent for Any NCPC 'No NCPC'. ^¥^ Sex, age, race/ethnicity, education, income, Medicaid insurance, private insurance, marital status, region. ^¥¥^ Smoking status, body mass index, hypertension, diabetes, heart disease, cancer, respiratory illnesses, history of stroke and traumatic brain injury.
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###### 

Association of baseline non-cancer chronic pain conditions (NCPC's) and burden to incident Alzheimer's disease and related dementias in older Medicare beneficiaries \*: analysis using linked Medicare Current Beneficiary Survey and Medicare claims data, 2001--2013: Potential mediating influence of diagnosed mood and sleep disorders (odds ratios (OR) and adjusted odds ratios (AOR) with 95% confidence intervals (CI)).

  NCPC Presence/Number           Fully Adjusted Model ^¥^   Model ^¥^ + Mood Disorders ^§^   Model ^¥^ + Sleep Disorders ^§§^   Model ^¥^ + Mood and Sleep Disorders                                                    
  ------------------------------ -------------------------- -------------------------------- ---------------------------------- -------------------------------------- ------------------ ---------- ------------------ ----------
  **Any NCPC vs. None \*\***     1.25 (1.08,1.45)           0.0032                           1.17 (1.01,1.37)                   0.0388                                 1.20 (1.04,1.39)   0.0155     1.18 (1.01,1.38)   0.0336
  **Number of NCPCs**                                                                                                                                                                                                   
   None (referent)               1.00 (referent)                                             1.00 (referent)                                                           1.00 (referent)               1.00 (referent)    
   One                           1.23 (1.04,1.45)           0.0179                           1.19 (1.01,1.41)                   0.0408                                 1.20 (1.02,1.43)   0.0311     1.17 (0.99,1.39)   0.0594
   Two                           1.20 (1.01,1.43)           0.0435                           1.13 (0.95,1.36)                   0.1722                                 1.16 (0.97,1.38)   0.1008     1.11 (0.92,1.32)   0.2713
   Three                         1.34 (1.07,1.68)           0.0122                           1.22 (0.96,1.55)                   0.0962                                 1.25 (0.99,1.58)   0.0589     1.17 (0.92,1.48)   0.2112
   Four or more                  1.91 (1.31,2.80)           0.0008                           1.57 (1.06,2.34)                   0.0255                                 1.66 (1.12,2.45)   0.0113     1.41 (0.94,2.12)   0.0941
  ***p for linear trend*^++^**                              \<0.0001                                                            \<0.0001                                                  \<0.0001                      \<0.0001
  **Number of NCPCs**                                                                                                                                                                                                   
  (per additional NCPC)          1.12 (1.05,1.20)           0.0007                           1.08 (1.01,1.16)                   0.027                                  1.09 (1.02,1.16)   0.0101     1.06 (0.99,1.13)   0.1001

\* Based on 11 pooled cohorts of older community-dwelling adults (age \> 65 years), enrolled in fee-for-service Medicare. \*\* Including back or neck pain, headache and migraine, joint pain, neuropathic pain, and osteoarthritis. ^¥^ sex, age, race/ethnicity, education, income, Medicaid insurance, private insurance, marital status, region, smoking status, body mass index, chronic physical health conditions (hypertension, diabetes, heart disease, cancer, respiratory disorder, history of stroke, traumatic brain injury), NSAID and opioid analgesics. ^§^ Depression and anxiety; ^§§^ insomnia-related sleep disorders. ^++^ Regression results from polynomial contrast for linear relation indicate a strong linear effect of NCPC on risk of ADRD.
